Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan · Delayed Price · Currency is JPY 5,715.00
+24.00 (0.42%)
Aug 27, 2026, 9:52 AM JST
Kobayashi Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 167,473 | 165,742 | 165,600 | 173,455 | 166,258 | 155,252 | |
Revenue Growth | 3.71% | 0.09% | -4.53% | 4.33% | 7.09% | 3.15% |
Cost of Revenue | 82,575 | 81,030 | 77,997 | 77,079 | 73,927 | 66,478 |
Gross Profit | 84,898 | 84,712 | 87,603 | 96,376 | 92,331 | 88,774 |
Selling, General & Admin | 58,798 | 54,126 | 48,040 | 57,457 | 53,902 | 52,072 |
Research & Development | 9,122 | 9,122 | 9,109 | 9,004 | 8,327 | 7,522 |
Amortization of Goodwill & Intangibles | 1,390 | 1,390 | 1,407 | 1,128 | 998 | 862 |
Other Operating Expenses | 1,264 | 1,264 | 753 | 930 | 767 | 718 |
Operating Expenses | 74,539 | 69,867 | 62,893 | 70,749 | 65,825 | 62,823 |
Operating Income | 10,359 | 14,845 | 24,710 | 25,627 | 26,506 | 25,951 |
Interest Expense | -26 | -28 | -28 | -29 | -18 | -18 |
Interest & Investment Income | 1,133 | 999 | 815 | 762 | 578 | 588 |
Currency Exchange Gain (Loss) | 597 | 278 | 330 | 40 | 231 | 481 |
Other Non Operating Income (Expenses) | 690 | 900 | 1,033 | 930 | 983 | 1,011 |
EBT Excluding Unusual Items | 12,753 | 16,994 | 26,860 | 27,330 | 28,280 | 28,013 |
Gain (Loss) on Sale of Investments | 3,392 | 3,041 | 635 | 436 | -89 | 84 |
Gain (Loss) on Sale of Assets | 2,012 | 2,119 | -51 | -59 | -52 | -70 |
Asset Writedown | -14,775 | -14,775 | - | -59 | -69 | -309 |
Other Unusual Items | -1,669 | -3,636 | -13,531 | -89 | -121 | -83 |
Pretax Income | 1,713 | 3,743 | 13,913 | 27,559 | 27,949 | 27,635 |
Income Tax Expense | 80 | 83 | 3,842 | 7,221 | 7,927 | 7,920 |
Earnings From Continuing Operations | 1,633 | 3,660 | 10,071 | 20,338 | 20,022 | 19,715 |
Minority Interest in Earnings | -8 | -4 | -4 | - | - | - |
Net Income | 1,625 | 3,656 | 10,067 | 20,338 | 20,022 | 19,715 |
Net Income to Common | 1,625 | 3,656 | 10,067 | 20,338 | 20,022 | 19,715 |
Net Income Growth | -86.23% | -63.68% | -50.50% | 1.58% | 1.56% | 2.66% |
Shares Outstanding (Basic) | 74 | 74 | 74 | 76 | 77 | 78 |
Shares Outstanding (Diluted) | 74 | 74 | 74 | 76 | 77 | 78 |
Shares Change | - | - | -1.98% | -1.67% | -1.27% | -0.05% |
EPS (Basic) | 21.86 | 49.18 | 135.42 | 268.16 | 259.61 | 252.35 |
EPS (Diluted) | 21.86 | 49.18 | 135.42 | 268.16 | 259.59 | 252.35 |
EPS Growth | -86.23% | -63.68% | -49.50% | 3.30% | 2.87% | 2.71% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -5,956 | 12,337 | -14,810 | 5,604 | 17,167 | 18,756 |
Free Cash Flow Per Share | -80.12 | 165.96 | -199.22 | 73.89 | 222.57 | 240.08 |
Dividend Per Share | 60.000 | 104.000 | 102.000 | 101.000 | 90.000 | 83.000 |
Dividend Growth | -41.75% | 1.96% | 0.99% | 12.22% | 8.43% | 7.79% |
Gross Margin | 50.69% | 51.11% | 52.90% | 55.56% | 55.54% | 57.18% |
Operating Margin | 6.19% | 8.96% | 14.92% | 14.77% | 15.94% | 16.71% |
Profit Margin | 0.97% | 2.21% | 6.08% | 11.72% | 12.04% | 12.70% |
Free Cash Flow Margin | -3.56% | 7.44% | -8.94% | 3.23% | 10.33% | 12.08% |
EBITDA | 19,560 | 23,590 | 32,732 | 31,684 | 31,864 | 30,786 |
EBITDA Margin | 11.68% | 14.23% | 19.77% | 18.27% | 19.16% | 19.83% |
D&A For EBITDA | 9,201 | 8,745 | 8,022 | 6,057 | 5,358 | 4,835 |
EBIT | 10,359 | 14,845 | 24,710 | 25,627 | 26,506 | 25,951 |
EBIT Margin | 6.19% | 8.96% | 14.92% | 14.77% | 15.94% | 16.71% |
Effective Tax Rate | 4.67% | 2.22% | 27.61% | 26.20% | 28.36% | 28.66% |
Advertising Expenses | - | 16,862 | 11,575 | 23,038 | 22,389 | 22,499 |